Chemotherapie-induzierte periphere Neuropathie

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a severe and common side effect induced by a variety of anticancer drugs. CIPN presents as a sensory, motor, and sometimes autonomic dysfunction with a large variability, from a mild tingling sensation and hyperesthesia, to severe neuropathic pain. Up to 40 % of patients will develop CIPN which may lead to dose-reduction or discontinuation of their current treatment and largely affects their quality of life (QoL). This review presents specific clinical features and pathomechanisms and discusses current preventive strategies and therapeutic options.

Die Chemotherapie-induzierte periphere Neuropathie (CIPN) ist eine häufige Nebenwirkung bei antineoplastischen Therapien mit substanzspezifischer Varianz. Auch zielgerichtete Substanzen können zur CIPN führen, was ein relevantes klinisches Problem darstellt, da dies häufig zu Dosisreduktion oder gar zum Abbruch der Behandlung führt. Dieser Beitrag gibt eine Übersicht über Pathophysiologie, klinische Symptomatik, Diagnostik und Therapieoptionen.

Schlüsselwörter

Chemotherapie-induzierte periphere Neuropathie (CIPN) - Vincaalkaloide - Platinderivate, Prävention

Key words

chemotherapy induced peripheral neuropathy (CIPN) - vinca alkaloids - platinumcompounds - prevention

• Literatur

• 1 Seretny M, Currie GL, Sena ES. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014; 155: 2461-2470
• 2 Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Br J Anaesth 2017; 119: 737-749
• 3 Deutsche Krebsgesellschaft. Leitlinienprogramm Onkologie: Supportive Therapie bei onkologischen PatientInnen – Langversion 1.1. 2017 AWMF Registernummer: 032/054OL. Im Internet: http://www.leitlinienprogramm-onkologie.de/index.php?id=95&type=0 Stand: 19.04.2018
• 4 Briani C, Vitaliani R, Grisold W. et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology 2011; 76: 705-710
• 5 Staff NP, Grisold A, Grisold W. et al. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017; 81: 772-781
• 6 Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 2010; 6: 657-666
• 7 Cavaletti G, Frigeni B, Lanzani F. et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007; 12: 210-215
• 8 Cavaletti G, Cornblath DR, Merkies IS. et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013; 24: 454-462
• 9 Argyriou AA, Bruna J, Marmiroli P. et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012; 82: 51-77
• 10 Frigeni B, Piatti M, Lanzani F. et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. Journal of the peripheral nervous system 2011; 16: 228-236
• 11 Sittl R, Lampert A, Huth T. et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: 6704-6709
• 12 Pachman DR, Qin R, Seisler DK. et al. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol 2015; 33: 3416-3422
• 13 Kerckhove N, Collin A, Conde S. et al. Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front Pharmacol 2017; 8: 86
• 14 Reeves BN, Dakhil SR, Sloan JA. et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 2012; 118: 5171-5178
• 15 Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012; 203: 194-206
• 16 Cortes J, Vahdat L, Blum JL. et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28: 3922-3928
• 17 Chen R, Gopal AK, Smith SE. et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016; 128: 1562-1566
• 18 Tay CG, Lee VWM, Ong LC. et al. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. Pediatric blood & cancer 2017; 64
• 19 Geisler S, Doan RA, Strickland A. et al. Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. Brain 2016; 139: 3092-3108
• 20 Richardson PG, Briemberg H, Jagannath S. et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24: 3113-3120
• 21 Moreau P, Pylypenko H, Grosicki S. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet. Oncology 2011; 12: 431-440
• 22 Niesvizky R, Hungria V, Ho J. et al. Rates of peripheral neuropathy (PN) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM) treated with carfilzomib vs comparators in pivotal phase III trials. Journal of Clinical Oncology 2017; 35: 8041-8041
• 23 Kumar S, Moreau P, Hari P. et al. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. British Journal of Haematology 2017; 178: 571-582
• 24 Bringhen S, De Wit E, Dimopoulos MA. New Agents in Multiple Myeloma: An Examination of Safety Profiles. Clin Lymphoma Myeloma Leuk 2017; 17: 391-407
• 25 Tosi P, Zamagni E, Cellini C. et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European journal of haematology 2005; 74: 212-216
• 26 Kirchmair R, Tietz AB, Panagiotou E. et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Molecular therapy : the journal of the American Society of Gene Therapy 2007; 15: 69-75
• 27 Astaras C, de Micheli R, Moura B. et al. Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Curr Neurol Neurosci Rep 2018; 18: 3
• 28 Loprinzi CL, Qin R, Dakhil SR. et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 2014; 32: 997-1005
• 29 Hershman DL, Lacchetti C, Dworkin RH. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941-1967
• 30 Smith EM, Pang H, Cirrincione C. et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309: 1359-1367
• 31 Smith EM, Pang H, Ye C. et al. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial – CALGB/alliance 170601. Eur J Cancer Care (Engl) 2017; 26